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radiotherapy alone. Direct and indirect costs were derived from published peer-
reviewed literature or government data. Utilities were obtained from a previously
published cost-utility analysis of temozolomide and carmustine wafers in newly
diagnosed glioblatoma. Univariate and threshold sensitivity analyses were con-
ducted on all survival data, input costs, utilities, and other important parameters.
RESULTS: The addition of temozolomide to the standard radiotherapy regimen
was associated with a base-case incremental cost-effectiveness ratio of $154,933
per quality-adjusted life-year. This is considerably higher than the only other com-
parable estimate, which assumed the perspective of the UK National Health Ser-
vice and did not include indirect costs. The model was most sensitive to the utility
associated with the use of temozolomide during the maintenance phase of stable
disease treatment. CONCLUSIONS: The base-case incremental cost-effectiveness
ratio lies just beyond a willingness-to-pay threshold of $150,000 per quality-ad-
justed life-year. However, sensitivity analysis revealed numerous plausible scenar-
ios that produced lower estimates. Notably, a 10% increase in the utility associated
with stable disease treatment produced an estimate of $120,743 per quality-ad-
justed life-year. Given these results and the lack of alternative treatments for glio-
blastoma, we conclude that temozolomide’s use in this setting is not definitively
cost-effective. However, better estimates of relevant health state utilities could
greatly improve cost-effectiveness models for glioblastoma treatments.
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OBJECTIVES: To determine the costs, outcomes and level of cost-effectiveness
associated with HPV vaccination in urban China. METHODS: A Markov model of
HPV vaccination in urban China is used to follow hypothetical females from age 12
to age 92. The individuals in the model are assumed to be vaccinated at age 12 and
the rates of HPV infection, squamous intraepithelial lesions, cervical cancer and
death are measured on an annual basis for 80 years. All costs and outcomes are
discounted. RESULTS: In our base case analysis, the administration of HPV vaccine
could reduce cervical cancer rate by 65%. In ourmodel, HPV vaccination is found to
be cost-saving. The implementation of HPV vaccination results in an increase of 0.6
QALYs over the lifetime of each individual. The total lifetime discounted costs with
vaccination are $766 dollars per individual lower than the total costs without vac-
cination. Under all scenarios examined in our sensitivity analysis, the total costs
with vaccination are reduced when compared to current practice with an increase
in QALYs as well. CONCLUSIONS: Compared to current practice in China, which
does not include cervical cancer screening, HPV vaccination appears to be cost-
saving. China has a coverage rate of 95% for its childhood immunization program.
Incorporating HPV vaccination into this program could likely be done with a min-
imal amount of effort. Our results provide strong evidence for the implementation
of HPV vaccination programs in urban China.
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OBJECTIVES: The purpose of this research was to determine the cost-effectiveness
of sunitinib in terms of the RF health care system. In this research, the comparisons
of costs and effectiveness with patients treated by sunitinib, IFN-, sorafenib and
bevacizumab with IFN- were studied, based on the RF health care system
conditions.METHODS: In this Pharmacoeconomic research the cost-effectiveness
analysis (CEA) and cost-utility analysis (CUA) were studied. The results were esti-
mated in life years before the disease progression (PfLYs) and prolonged life years
(LYs)within CEA andquality-adjusted life-years (QALYs)within CUA. The results of
these analyses were illustrated in incremental cost-effectiveness rate (ICER) and
cost-utility rate (ICUR). The cost-utility analysis was chosen as the main analytical
method, because sunitinibwas supposed not only to affect survivability but quality
of life as well. RESULTS: The data of the research illustrates that sunitinib usage as
a first-line drug for mRCC patients provides a significant health improvement in
terms of PFS and OS, expressed in ICER index, equal to 3,742,060 rub and 955 451 for
a saved life year, and ICUR index, equal to 6,787,955 rub and 2,912,714 rub for QALY
in comparison with IFN- and sorafenib respectively. High values of these indexes
are mainly caused by high cost of sunitinib and relatively low cost of healthcare
resources in Russian Federation. In comparison with bevacizumab with IFN-,
sunitinib is dominant, providing better efficacy with lower cost. CONCLUSIONS:
These results suggest that sunitinib is a cost-effective alternative to sorafenib,
bevacizumab with IFN-, and sorafenib as a first-line treatment of mRCC.
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OBJECTIVES: To evaluate the health-related quality of life (HRQOL) and to compare
direct medical, non-medical and indirect cost of stage III colorectal cancer(CRC)
patients receiving either capecitabine-based or 5-FU/LV-based adjuvant treat-
ments from societal perspective. METHODS: An observational follow-up study to
collect HRQOL and cost data from stage III CRC patients were conducted in 12
hospitals from 2008 to 2010. A total of 535 patients were invited to complete ques-
tionnaires during the study period: at study baseline (Q0), at 3 months after the
initial adjuvant treatment (Q3), and at 1 month after treatment had finished (Q7)
using the EORTC QLQ-C30 and QLQCR-38 questionnaires. Cost data were obtained
fromNational Health Insurance Research Database (NHIRD), patient questionnaire
(Q3) and productivities loss from Manpower Utilization Survey. 66% of patients
completed the questionnaire as per protocol and their data were the basis for
further analysis. Propensity score matching (PSM) method was used to reduce
selection bias and to avoid endogenous problems by matching variables, i.e. age,
gender, location of tumor, marital status, education, work and the number of co-
morbidities between two groups. After PSM, a total of 239 patients were analyzed.
RESULTS: In capecitabine-based treatment, Physical, Role, Emotional, Social,
Global Health status, Body Image, Future perspective Functioning, Fatigue, Pain,
Diarrhea, Stoma-related problem, and Weight loss Symptoms were all improved
from Q0 to Q3 and Q0 to Q7. In 5-FU/LV-based treatment, Physical, Role, Social,
Global health status Functioning, GI tract and Weight loss Symptoms also im-
proved. Total directmedical, direct non-medical, and indirect cost of capecitabine-
based and 5-FU/LV-based treatment were NT$29,452 (USD $982) and NT$55,200
(USD $1,840), respectively.CONCLUSIONS:This real-life study shows that adjuvant
chemotherapy has no negative impact on HRQOL during study period. Capecit-
abine-based treatment performs better in most functioning aspects of HRQOL and
is cost-saving in direct and indirect resources utilization from societal perspective.
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OBJECTIVES: To assess the cost-effectivness of lenalidomide in treatment of the
second and third lines of multiple myeloma in the Russian Federation.METHODS:
We developed an economic model of multiple myeloma disease to calculate the
cost of diagnosis and treatment of second and third-line therapy of lenalidomide
and bortezomib. The efficacy of drugs (time to progression- TTP)was obtained from
clinical trials: MM - 009/-010 for lenalidomide; APEX for bortezomib. TTP for lena-
lidomide was 21.2 months and for bortezomib - 16.4 months. Medical care costs
were estimated from the standard of multiple myeloma treatment, which was
developed and published by Ministry of public health. RESULTS: A CER of lenalido-
mide in the second line therapy was 468,110,84 RUB (11,529,82 €) which is lower
then use of bortezomib in the second line therapy 605 118,89 RUB (14,904,4 €).
CONCLUSIONS: Application of lenalidomide in second-line therapy of multiple
myeloma is dominated alternative of treatment.
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OBJECTIVES: Formany years, the backbone of cancer treatment has been the use of
cytotoxic agents. There has been an emergence of new drugs, however, that are
more specific to the target. Some of these agents have resulted in a prolongation of
survival and even clinical cures in some cancers. In order to compare and contrast
the costs and benefits of these new drug therapies, a descriptive evaluation across
seven major tumour types was undertaken. METHODS: A literature search was
conducted from 2000 to 2011 to identify randomized trials of novel therapies in
breast, lung, colorectal, kidney, lymphoma, multiple myeloma and chronic my-
elogenous leukemia. Clinical outcomes in terms of progression free (PFS) and over-
all survival (OS) benefit were extracted. Economic data in terms of cost per month
of therapy was obtained from a U.S. cancer clinic. RESULTS: Approximately 22
novel therapies were approved across the seven cancers. Four of the 22 (18%) were
used with a curative intent while the remainder were used in the palliative setting
(n18). Ten of these 18 (56%) latter agents also demonstrated an OS benefit. The
median month cost for novel therapies used with a curative intent and those with
a survival benefit in the palliative setting were $5450 and $6450 respectively. In
contrast, the median monthly cost for drugs that did not offer either of these
benefits was $7900. Of the agents identified, imatinib, lenalidomide, rituximab and
trastuzumab provided the greatest magnitude of benefit for both PFS and OS and
would be considered major clinical advances. CONCLUSIONS: Approximately 64%
of novel drugs approved over the past 11 years are used with a curative intent or
provide a survival benefit in the palliative care setting. Themonthly cost for agents
not providing these benefits, however,was higher, indicating a disconnect between
efficacy and cost.
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OBJECTIVES: To identify which is the chemotherapy scheme alternative that
minimizes costs in the 1st line treatment of Metastatic Colorectal Cancer
(mCRC) in Mexico.METHODS: Costminimization comparing different chemother-
apy schemes for mCRC: XELOX (CapecitabineOxaliplatin), FOLFOX-4
(OxaliplatinFluorouracilfolinic acid), FOLFOX-6 (Oxaliplatin Fluorouracil fo-
linic acid) and FOLFIRI (IrinotecanFluorouracilfolinic acid). It was performed a
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Markov model with 3 stages: disease progression, disease free progression and
death in a time horizon of 3 years. Costs were based on direct medical costs of the
institution, drug administration costs and cost for the management of adverse
events and they are expressed in US dollars. RESULTS: The average treatment cost
for the alternatives were: $ 16,133.78 for XELOX, $ 25,690.58 for FOLFOX-4, $
27,686.35 for FOLFOX-6 and $ 21,904.12 for FOLFIRI. XELOX is the least costly alter-
native. The difference in costs ismainly due to the difference inmanagement costs
and the presence of grade 3-4 adverse events, mainly neutropenia. Based on clin-
ical trials, FOLFOX-6 presented neutropenia (47%), FOLFOX-4 (44%) and FOLFIRI
(26%), while the most severe adverse event was diarrhea with XELOX (12%). In the
disease management, FOLFOX-6, FOLOFX-4 and FOLFIRI require two hospitaliza-
tions per cycle for the application of the drug. Instead, XELOX requires only one
chemotherapy session. Since Capecitabine is orally administered, not only mini-
mizes the costs of administration, also has a better safety profile with less adverse
events. CONCLUSIONS: The use of Capecitabine combined with Oxaliplatin
scheme as first-line treatment of metastatic colorectal cancer, is the alternative
that minimizes costs to the health institutions, as well as improve quality of life
resulting from Capecitabine’s oral administration.
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OBJECTIVES: To identify which of the different chemotherapy alternatives minimizes
costs for the treatment of advanced and/or metastatic Gastric Cancer (GC) in Mexico.
METHODS: A cost minimization was performed considering the alternatives: EOX
(epirubicinoxaliplatincapecitabine), EOF (epirubicinoxaliplatinfluorouracil),
ECX (epirubicincisplatincapecitabine) and ECF (epirubicincisplatin fluorou-
racil) for the treatment of advanced and/ormetastatic gastric cancer (advGA) using
aMarkovmodel with 3 stages: progression, disease free progression and death. For
a time horizon of 3 years, it was taken into account direct medical costs for the
diseasemanagement, drug and its application cost, and costs incurred in theman-
agement of the associated adverse events. Costs are expressed in USD dollars.
RESULTS: ECXwas the alternativewith less costs ($6,293), followed by EOX ($7,692).
The chemotherapy combinations based on capecitabine proved to be the least
expensive. The alternative EOF had a cost of $10,904, while ECF was $9,873. The
factor that increased costs of EOF and ECF was the drug administration costs, as
they require to be administered as daily intravenous infusions in comparison of the
oral administration of capecitabine. Therefore, the administration costs of ECX and
EOX represent only 4.76% of the administration costs of ECF and EOF. The results of
the univariate sensitivity analysis confirmed savings with capecitabine versus ECF
from$5,721 to $6,209 and versus EOF from$5,691 to $6,178 in the totalmanagement
costs. The probabilistic analysis results also confirmed that in the ECF scheme
versus ECX, the combination with capecitabine is a cost-saving alternative. ECX
and EOX are alternatives that minimize costs at 100% of cases compared to ECF
and EOX respectively. CONCLUSIONS: The oral administration of capecitabine is
the factor that minimizes the cost of the alternatives in the chemotherapy combi-
nation schemes, also, the safety profile of capecitabine helps incurring in less costs
associated to the management of side adverse events.
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OBJECTIVES: CML is a clonal myeloproliferative neoplastic disorder characterized
by a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11) lead-
ing to the formation of the BCR-ABL fusion gene.With the introduction of imatinib,
a BCR-ABL tyrosine kinase inhibitor (TKI), survival has improvedwith durable long-
term responses. Nilotinib is a more recently approved second generation TKI indi-
cated for treatment of CML as first- and second-line therapy. Shorter-term clinical
trials (24months) have shown that nilotinib produces a faster cytogenetic response
compared to imatinib, but long-term survival outcomes have not yet been reported
in clinical trials. The objective of this analysis is to explore the cost-effectiveness of
nilotinib compared to imatinib for the treatment of newly diagnosed CML in
chronic phase. METHODS: Using a healthcare payer perspective, a 72-month
Markov state transition model was developed in Microsoft Excel 2007. Major cyto-
genetic response, progression, and survival rates were obtained from a 24-month
head-to-head clinical trial and a 72-month single arm trial evaluating long-term
responses with imatinib. Nilotinib as a second-line therapy was allowed for pa-
tients who progressed while on imatinib. Drug costs were obtained from the Red
Book. Hospital and outpatient costs were obtained from reimbursement rates from
the Centers for Medicare and Medicaid Services. Sensitivity analyses were con-
ducted to test various assumptions. RESULTS: The base case analysis resulted in
0.1 life years gained for nilotinib compared to imatinib. Resultant quality-adjusted
life years (QALYs) for nilotinib and imatinib were estimated to be 4.39 and 4.23,
respectively. The additional cost for treating with nilotinib was $213,895, resulting
in an incremental cost effectiveness ratio (ICER) of greater than 1million dollars per
QALY saved. CONCLUSIONS: Based upon this analysis, the small additional sur-
vival benefits associated with nilotinib do not translate into a favorable ICER for
first-line treatment of CML in chronic phase.
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BACKGROUND: Approximately 60% of breast cancer cases are hormone sensitive.
Tamoxifen is the most widely used treatment of hormone-dependent breast can-
cer. The pharmacological activity of tamoxifen is dependent on its conversion by
the hepatic drug-metabolizing enzyme CYP2D6. Patients with reduced CYP2D6
activity may derive inferior therapeutic benefit from tamoxifen, and may alterna-
tively be treated with newer aromatase inhibitors (AIs) sequentially or as mono-
therapy. However, the higher costs of AIs provide incentive for identifying patients
who will benefit from tamoxifen prior to treatment. OBJECTIVES: To evaluate the
cost-effectiveness of adjuvant mono and sequential hormone therapies, and
CYP2D6 testing in combination with tamoxifen mono and sequential (with AIs)
therapies for ER hormone sensitive women with early breast cancer in Canada.
METHODS:Weperformed a cost-effectiveness analysis using aMarkovmodel from
a societal perspectivewith a lifetime horizon. An embedded decision treewas used
to identify best treatment strategy according to CYP2D6 gene polymorphisms. Our
comparator is optimal treatment strategy without genetic testing. Patient popula-
tion is 65-year-old ER hormone sensitive women with early breast cancer. Ex-
pected value of perfect information was performed to identify future research
directions. Probabilistic sensitivity analysis was used to incorporate parameter
uncertainties. Outcomes were quality-adjusted life years (QALYs) and costs.
RESULTS: Our preliminary analysis suggested that the genetic testing and treat-
ment combination strategy were marginally more effective (0.005 QALY gained)
and cost CAD $102 more when compared to no testing (letrozole-tamoxifen se-
quential therapy). The incremental cost-effectiveness ratio (ICER) for the base case
was $21,732 per QALY. The results were sensitive to assumptions related to disease
progression,mortality rate and the drug cost. CONCLUSIONS: Themarginal gain in
effectiveness and extra cost may not warrant a recommendation for routine
CYP2D6 genetic testing in combination with tamoxifen monotherapy for ER
women with early breast cancer in the current setting.
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OBJECTIVES: The cost-effectiveness analysis compares plerixafor GCSF for stem
cell mobilization in Canada compared to using GSCF alone or GCSF  chemother-
apy in patients with multiple myelemo (MM) or non-Hodgkins’s lymphoma (NHL)
whose cellsmobilize poorly. NHL andMMare severe forms of hematological cancer
where autologous hematopoietic stem cell (HSC) transplantation is a standard of
care in Canada. In order to proceed to transplantation, a sufficient number of stem
cells need to be harvested during apheresis. Patients who collect 2 million HSCs
proceed to transplant. Those whose peripheral blood CD34 cell count on the day
before apheresis is below the range of 10 to 20 cells/uL is generally considered a
poor mobilizer. METHODS: The model uses a cohort semi-Markov process that
embeds two decision trees for autologous transplantation and continuation of
care. The Markov structure based on annual cycles consists of three health states -
Remission, Well and Death. The mobilization decision tree includes the pre-
apheresis, apheresis and transplant pathways. The continuation of care includes a
series of therapies currently used in Canadian clinical practice following failed
mobilization or relapse. Patients enter remission after successful transplantation
and continuation of care after unsuccessful transplantation. RESULTS: The results
showed that incremental cost-effectiveness ratio (ICER) for plerixafor  GCSF
verses GCSF alone was $19,191 for NHL and $60,835 for MM. When compared to
GCSF  chemo, the ICER was $14,330 for NHL and $31,622 for MM patients. Deter-
ministic sensitivity analysis was conducted to assess extreme values and model
uncertainty. Probabilistic sensitivity analysis was conducted to generate cost-ef-
fectiveness acceptability curves. Major data limitations include probability of suc-
cessful mobilization and number of apheresis days for GCSFchemo comparator.
CONCLUSIONS: The results show that plerixafor  GCSF, when used in the poor
mobilizer setting, is a cost-effective strategy for both NHL and MM patients in
Canada.
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OBJECTIVES: To identify the drug that offers the best pharmacoeconomic result for
the treatment of advanced or metastatic NSCLC previously treated with a chemo-
therapy regimen in public health institutions in Mexico. METHODS: It was devel-
oped a cost-utility analysis using a Markov model with monthly cycles in a time
horizon of 2 years. Themain output indicators were: Years of Quality Adjusted Life
(QALY’s) and total treatment cost per patient. The alternatives in the study were:
Erlotinib, Docetaxel and Pemetrexed. Costs are expressed in US dollars. RESULTS:
The average cost per patient for Erlotinib was $9,862, and $21,583 to $24,049 for
Docetaxel and Pemetrexed. Erlotinib provided 0.33 QALY’s, while Docetaxel pro-
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